ZOLEDRONIC ACID FOR INJECTION CONCENTRATE SOLUTION

Land: Canada

Taal: Engels

Bron: Health Canada

Werkstoffen:

ZOLEDRONIC ACID (ZOLEDRONIC ACID MONOHYDRATE)

Beschikbaar vanaf:

STRIDES PHARMA CANADA INC

ATC-code:

M05BA08

INN (Algemene Internationale Benaming):

ZOLEDRONIC ACID

Dosering:

4MG

farmaceutische vorm:

SOLUTION

Samenstelling:

ZOLEDRONIC ACID (ZOLEDRONIC ACID MONOHYDRATE) 4MG

Toedieningsweg:

INTRAVENOUS

Eenheden in pakket:

100

Prescription-type:

Prescription

Therapeutisch gebied:

BONE RESORPTION INHIBITORS

Product samenvatting:

Active ingredient group (AIG) number: 0141761002; AHFS:

Autorisatie-status:

APPROVED

Autorisatie datum:

2014-06-24

Productkenmerken

Page
1
of
58
PRODUCT MONOGRAPH
PR
ZOLEDRONIC ACID FOR INJECTION CONCENTRATE
4 mg zoledronic acid/5 mL incorporated as the monohydrate for
intravenous infusion
BONE METABOLISM REGULATOR
Strides Pharma Canada Inc.
Date of Revision:
1565, Boul. Lionel-Boulet
August 11, 2020
Varennes, Quebec
Canada, J3X 1P7
Submission Control No.: 241322
Page
2
of
58
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
......................................................... 3
SUMMARY PRODUCT INFORMATION
...............................................................................
3
INDICATIONS AND CLINICAL USE
.....................................................................................
3
CONTRAINDICATIONS
..........................................................................................................
3
WARNINGS AND PRECAUTIONS
.........................................................................................
4
ADVERSE REACTIONS
.........................................................................................................
13
DRUG INTERACTIONS
.........................................................................................................
23
DOSAGE AND ADMINISTRATION
.....................................................................................
23
OVERDOSAGE
.......................................................................................................................
27
ACTION AND CLINICAL PHARMACOLOGY
................................................................... 28
STORAGE AND STABILITY
.................................................................................................
32
DOSAGE FORMS, COMPOSITION AND PACKAGING
.................................................... 32
PART II: SCIENTIFIC INFORMATION
...............................................................................
34
PHARMACEUTICAL INFORMATION
.................................................................................
34
CLINICAL TRIALS
.........................................